TABLE 3.

Pharmacokinetic (PK) model simulations of attainment of PK targets of trough infliximab (IFX) concentrations of >3 mg/ml, >4 mg/ml, or >5 mg/ml for anti‐IFX antibody negative (ADA−) or positive (ADA+) patients in case of safety pausing IFX therapy in the entire third trimester of pregnancy (IFX‐stop); continuation of steady IFX maintenance therapy in the third trimester of pregnancy (IFX cont.); and nonpregnant patients receiving standard IFX maintenance therapy

	Pregnant, IFX‐stop in third trimester	Pregnant, IFX cont. in third trimester	Nonpregnant patients
ADA−	%n  > 3 μg/ml = 30	%n  > 4 μg/ml = 65	%n  > 4 μg/ml = 51
	%n  > 4 μg/ml = 19	%n  > 5 μg/ml = 52	%n  > 5 μg/ml = 39
	%n  > 5 μg/ml = 11	%n  > 3 μg/ml = 41	%n  > 3 μg/ml = 28
ADA+	%n  > 3 μg/ml = 3	%n  > 4 μg/ml = 17	%n  > 4 μg/ml = 11
	%n  > 4 μg/ml = 1	%n  > 5 μg/ml = 9	%n  > 5 μg/ml = 5
	%n  > 5 μg/ml = 1	%n  > 4 μg/ml = 3	%n  > 4 μg/ml = 2